AdvaMed warns fragmentation is medtech’s biggest threat as the sector becomes more software-driven
AdvaMed is arguing that fragmentation, not lack of innovation, has become medtech’s central strategic risk. The warning reflects an industry increasingly constrained by disconnected data, siloed workflows, and uneven policy frameworks just as devices become more software-intensive and care pathways more integrated.
AdvaMed’s argument that fragmentation is medtech’s biggest threat is compelling because it identifies a problem that sits beneath many of the sector’s more visible frustrations. Companies can build powerful diagnostics, implants, and digital tools, but value leaks away when reimbursement, data systems, clinical workflows, and procurement structures remain disconnected.
This is especially true as medtech shifts toward software-enabled and AI-supported products. A device no longer succeeds only on technical performance; it must fit into an ecosystem of interoperability, evidence generation, clinician adoption, cybersecurity, and service support. Fragmentation turns each of those requirements into a separate negotiation, slowing scale and raising cost.
The industry implication is that innovation policy can no longer focus narrowly on clearance pathways. Faster review is useful, but insufficient if health systems cannot implement products cleanly or if evidence standards vary too widely across stakeholders. In many cases, the bottleneck is not the invention but the connective tissue around it.
AdvaMed’s framing also doubles as a strategic prompt for industry self-reflection. Medtech companies have often contributed to fragmentation through proprietary architectures and isolated product strategies. If the sector wants to be treated as a partner in integrated care, it may need to compete less on lock-in and more on compatibility, workflow coherence, and shared infrastructure.